NCT02365506View on ClinicalTrials.gov

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 20, 2015

Primary Completion Date

May 13, 2016

Study Completion Date

June 13, 2016

Conditions
LQT2 Syndrome
Interventions
DRUG

Eleclazine

Tablets administered orally in a single dose

DRUG

Placebo

Placebo to match tablets administered orally in a single dose

Trial Locations (1)

14620

University of Rochester Medical Center/Strong Memorial Hospital, Rochester

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY